glp 1 for cardiovascular The effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Can GLP-1 agonists treat cardiovascular

Obesity is a significant medical concern, and while Wegovy represents a crucial treatment option, Sockalingam emphasized that the medication shouldnt be viewed as a cosmetic solution for shedding a quick 15 pounds

Additional safety considerations include: Acute pancreatitis risk : Patients should be monitored for severe abdominal pain Gallbladder disease : Including cholelithiasis and cholecystitis Dehydration and acute kidney injury : Particularly with gastrointestinal side effects Hypoglycemia : When used with insulin or sulfonylureas in patients with diabetes Diabetic retinopathy complications : Particularly with semaglutide in patients with pre-existing retinopathy Patients with hypothyroidism should undergo thyroid function monitoring when starting weight loss injections

1 The neuroprotection of glucagon like peptide-1 receptor agonists in neurodegenerative and cerebrovascular disorders Glucagon like peptide-1 (GLP-1) is a peptide called enteropancreatin secreted by small intestinal L cells

Semaglutide comes in three injected forms: Wegovy (2.4 mg / 7.2 mg weekly) for chronic weight management